Charles C. Wykoff
CHICAGO — Eyes with proliferative diabetic retinopathy treated with monthly aflibercept experienced a stable retinal nonperfusion area after 1 year compared with patients treated with quarterly aflibercept, according to a speaker here.
“Through the 1-year endpoint of the phase 2 randomized RECOVERY trial, there was evidence of a dose response with reduction of retinal nonperfusion progression with monthly compared to quarterly dosing,” Charles C. Wykoff, MD, said at the American Society of Retina Specialists annual meeting.
Wykoff presented the 1-year results of the RECOVERY trial, a 2-year trial evaluating the mean change in retinal nonperfusion area from baseline in eyes with proliferative diabetic retinopathy without diabetic macular edema. Patients received monthly intravitreal Eylea (aflibercept, Regeneron) 2 mg or quarterly intravitreal aflibercept 2 mg. Twenty patients were in each arm of the study.
At 1 year, patients in the monthly cohort remained stable at 264 mm2 in total area of retinal nonperfusion. However, patients in the quarterly cohort experienced a 29% increase in retinal nonperfusion area, from 207 mm2 at baseline to 268 mm2 at 12 months, a statistically significant increase (P = .01).
“Certainly, across the combined population and either population on its own, there was no significant evidence of widespread reperfusion. Nonetheless, there were small localized areas of reperfusion that did appear to be identifiable,” Wykoff said. – by Robert Linnehan
Wykoff CC. Intravitreal aflibercept for retinal nonperfusion in proliferative diabetic retinopathy: one-year primary outcomes from the randomized RECOVERY trial. Presented at: American Society of Retina Specialists annual meeting; July 27-30, 2019; Chicago.
Disclosure: Wykoff reports financial disclosures for Regeneron. The investigator-initiated trial was funded by a grant from Regeneron.